DelveInsight’s, “C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) – Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the C-MET Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-MET Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the C-MET Non-Small Cell Lung Cancer Pipeline Report

• DelveInsight’s C-MET Non-Small Cell Lung Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for C-MET Non-Small Cell Lung Cancer treatment.
• The leading companies working in the C-MET Non-Small Cell Lung Cancer Market include AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
• Promising C-MET Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include PF-02341066, Telisotuzumab vedotin, Amivantamab, Lazertinib, Carboplatin, Pemetrexed, PLB1001, and others.
• October 2023: Mythic Therapeutics announced a study of Phase 1 clinical trials for MYTX-011. This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE). The study will be conducted in 2 parts. Part 1 will assess the safety and tolerability of MYTX-011 and identify the dose to be studied in Part 2. Part 2 will include subjects with NSCLC with cMET overexpression or MET amplification/exon 14 skipping mutations, populations with a current unmet medical need.
• October 2023: AbbVie announced a study of Phase 2 clinical trials for Telisotuzumab Vedotin. Participants will receive IV telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria. Telisotuzumab vedotin is an investigational drug being developed for the treatment of MET amplified non-squamous NSCLC. Participants receive intravenously (IV) infused of telisotuzumab vedotin. Approximately 70 adult participants with previously untreated MET amplified locally advanced/metastatic non-squamous NSCLC will be enrolled in the study in approximately 110 sites worldwide.
• October 2023: Apollomics Inc. announced a study of Phase 2 clinical trials for APL-101 Oral Capsules. Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors. Efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET.
• October 2023: Janssen Research & Development LLC announced a study of Phase 1 clinical trials for Lazertinib, Amivantamab, Carboplatin and Pemetrexed. The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (JNJ-61186372) (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced non-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B, C, D and E), to estimate the antitumor activity of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced NSCLC with documented advanced or metastatic EGFR mutation (Phase 1b expansion cohorts A, B, C, and D), to validate the biomarker identified in Phase 1b expansion Cohort D as a predictor of antitumor activity of Lazertinib and Amivantamab combination (Cohort E) or Amivantamab monotherapy (Cohort F) in participants with osimertinib-relapsed, chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC, to identify the recommended Phase 2 dose (RP2ChD) of Lazertinib when combined with Amivantamab and standard of care chemotherapy and to determine the tolerability of the Lazertinib, Amivantamab, and platinum-doublet chemotherapy (LACP) combination (Phase 1b LACP combination cohort) and to characterize the safety and tolerability of Lazertinib at the RP2ChD and Amivantamab and standard of care chemotherapy in participants with advanced or metastatic EGFR-mutated NSCLC (Phase 1b LACP combination cohort), to assess 2 potential biomarker strategies to identify participants at increased, or decreased, probability of tumor response with JNJ-61186372 and lazertinib combination in participants with EGFR Exon19del or L858R mutated NSCLC progressed on or after osimertinib (Phase 1b expansion Cohort D).

 

Request a sample and discover the recent advances in C-MET Non-Small Cell Lung Cancer Treatment Drugs @ C-MET Non-Small Cell Lung Cancer Pipeline Report

 

In the C-MET Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, C-MET Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, C-MET Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

C-MET Non-Small Cell Lung Cancer Overview

The role of the c-mesenchymal-epithelial transition factor (C-MET) signaling pathway in tumor progression and invasion has been extensively studied. C-MET inhibitors have shown anti-tumor activity in Non-Small Cell Lung Cancer both in preclinical and in clinical trials. However, given the molecular heterogeneity of Non-Small Cell Lung Cancer, it is likely that only a specific subset of Non-Small Cell Lung Cancer patients will benefit from c-MET inhibitors.

 

Find out more about C-MET Non-Small Cell Lung Cancer Therapeutics Assessment @ C-MET Non-Small Cell Lung Cancer Preclinical and Discovery Stage Products

 

C-MET Non-Small Cell Lung Cancer Emerging Drugs Profile

• JNJ-61186372: Janssen Research & Development, LLC
• PLB1001 – Beijing Pearl Biotechnology Limited Liability Company

 

C-MET Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC). The C-MET Non-Small Cell Lung Cancer companies that have their C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, etc.

 

DelveInsight’s C-MET Non-Small Cell Lung Cancer pipeline report covers around 20+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intramuscular
• Intratumoral
• Intravenous
• Molecule Type

 

C-MET Non-Small Cell Lung Cancer Pipeline Products have been categorized under various Molecule types such as

• Gene therapies
• Bispecific antibodies
• Immunotherapies
• Monoclonal antibodies
• Small molecules
• Product Type

 

Learn more about the emerging C-MET Non-Small Cell Lung Cancer Pipeline Therapies @ C-MET Non-Small Cell Lung Cancer Clinical Trials Assessment

 

Scope of the C-MET Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• C-MET Non-Small Cell Lung Cancer Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
• C-MET Non-Small Cell Lung Cancer Pipeline Therapies- PF-02341066, Telisotuzumab vedotin, Amivantamab, Lazertinib, Carboplatin, Pemetrexed, PLB1001, and others.

 

Dive deep into rich insights for new drugs for C-MET Non-Small Cell Lung Cancer Treatment, Visit @ C-MET Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals
9. Mid Stage Products (Phase II)
10. Telisotuzumab: AbbVie
11. PLB1001: Beijing Pearl Biotechnology Limited Liability Company
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. JNJ-61186372: Janssen Research & Development, LLC
15. Drug profiles in the detailed report…..
16. Pre-clinical and Discovery Stage Products
17. Drug profiles in the detailed report…..
18. Inactive Products
19. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
20. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products
21. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs
22. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers
23. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion
24. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views
25. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
26. Appendix   

 

For further information on the C-MET Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to C-MET Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market